MedMira has successfully
brought solutions for the rapid and simple diagnosis of
disease to healthcare markets around the world. Building
on our vision to bring leading edge technologies to healthcare
providers and their patients, MedMira Inc. has launched
a new division, Maple Biosciences.
Maple Biosciences will bring to market evolutionary
diagnostic instruments, displacing the current 30 year
old technology used to conduct routine lab tests. Aimed
at improving both the delivery of health care and the
patient experience, Maple Biosciences will enable reduced
specimen collection, reduced waiting time for results,
increased automation in the lab, and the streamlined
diagnosis of multiple conditions and diseases.
Maple Biosciences is developing new diagnostic instruments
based on biosensor technology that will be able to perform
highly complex lab tests in a matter of minutes. To achieve
our development goals, MedMira has acquired SensorChem
International, a company that was founded based on research
conducted by Professor Michael Thompson in the Department
of Chemistry at the University of Toronto. Dr. Thompson
is a pioneer in the field of biosensor technology and
has devoted much of his career to exploring the capabilities
of biosensors and their potential for commercial applications.
Dr. Thompson has also invested significant efforts in
securing the intellectual property for these inventions,
and many patents are held or pending for the biosensor
devices themselves as well as the chemistry methods required
to build lab tests for use with these instruments.
Click here to listen
to our webcast
Maple Biosciences
A Division
of
|